Symbols / PALI
PALI Chart
About
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 253.65M |
| Enterprise Value | 252.76M | Income | -11.23M | Sales | — |
| Book/sh | 0.35 | Cash/sh | 0.04 | Dividend Yield | — |
| Payout | 0.00% | Employees | 8 | IPO | — |
| P/E | — | Forward P/E | -7.39 | PEG | — |
| P/S | — | P/B | 4.83 | P/C | — |
| EV/EBITDA | -22.07 | EV/Sales | — | Quick Ratio | 1.51 |
| Current Ratio | 1.96 | Debt/Eq | 6.57 | LT Debt/Eq | — |
| EPS (ttm) | -2.05 | EPS next Y | -0.23 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-10 16:00 | ROA | -87.81% |
| ROE | -228.64% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 149.00M |
| Shs Float | 102.18M | Short Float | 14.16% | Short Ratio | 3.56 |
| Short Interest | — | 52W High | 2.64 | 52W Low | 0.53 |
| Beta | 1.61 | Avg Volume | 5.12M | Volume | 2.44M |
| Target Price | $13.40 | Recom | Strong_buy | Prev Close | $1.73 |
| Price | $1.70 | Change | -1.73% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$13.40
Mean price target
2. Current target
$1.70
Latest analyst target
3. DCF / Fair value
$-0.80
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.70
Low
$6.00
High
$25.00
Mean
$13.40
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-09 | init | B. Riley Securities | — → Buy | $7 |
| 2025-12-30 | init | Clear Street | — → Buy | $12 |
| 2025-12-29 | init | Piper Sandler | — → Overweight | $25 |
| 2025-05-13 | main | Brookline Capital | Buy → Buy | $16 |
| 2024-11-20 | init | Brookline Capital | — → Buy | $38 |
| 2024-11-13 | main | Maxim Group | Buy → Buy | $8 |
| 2024-05-01 | reit | Maxim Group | Buy → Buy | $23 |
| 2024-04-16 | main | Maxim Group | Buy → Buy | $23 |
| 2023-11-17 | up | Maxim Group | Hold → Buy | $2 |
| 2023-05-16 | main | Ladenburg Thalmann | Buy → Buy | $16 |
| 2023-03-30 | up | Maxim Group | Hold → Buy | $50 |
- Ulcerative colitis drug PALI-2108 gets boost from new IBD advisor - Stock Titan ue, 17 Feb 2026 13
- Palisade Bio Strengthens Clinical Advisory Board with Appointment of Dr. Bram Verstockt to Advance PALI-2108 Development in Ulcerative Colitis and Crohn's Disease - Quiver Quantitative ue, 17 Feb 2026 13
- Palisade Bio (PALI) chief medical officer Jones sells $3480 in stock - Investing.com Sat, 14 Feb 2026 01
- Here's Why Palisade Bio (PALI) Could be Great Choice for a Bottom Fisher - Yahoo Finance Mon, 10 Nov 2025 08
- Palisade Bio: Gut Prodrug For IBD With Catalysts - Seeking Alpha Mon, 22 Dec 2025 08
- Biotech Stocks Surge After Hours: PCSA, PALI, And QTTB Lead On Volume And Speculation - Nasdaq Wed, 08 Oct 2025 07
- Palisade Bio (NASDAQ:PALI) Lowered to Sell Rating by Wall Street Zen - MarketBeat Sat, 07 Feb 2026 08
- $138M Raised: Palisade Bio Closes Upsized Offering to Fund Phase 2 PALI-2108 - Stock Titan hu, 02 Oct 2025 07
- $PALI stock is down 8% today. Here's what we see in our data. - Quiver Quantitative hu, 15 Jan 2026 08
- Palisade Bio (PALI) Upgraded to Buy: Here's What You Should Know - Yahoo Finance Fri, 19 Dec 2025 08
- Two IBD leaders join Palisade Bio push on PALI-2108 for colitis and Crohn's - Stock Titan hu, 29 Jan 2026 08
- Palisade Bio, Inc. Announces Pricing of Public Offering of Common Stock Expected to Raise Approximately $120 Million - Quiver Quantitative Wed, 01 Oct 2025 07
- PALI-2108 patent No. 3,174,137 protects drug through May 28, 2041 — Palisade Bio targets FSCD & UC - Stock Titan Mon, 13 Oct 2025 07
- Palisade Bio Closes $138 Million Public Offering to Advance PALI-2108 for Ulcerative Colitis Development - Quiver Quantitative hu, 02 Oct 2025 07
- $120 Million Stock Offering: Biotech Palisade Bio Prices Massive 171.4M Share Public Offering at $0.70 - Stock Titan Wed, 01 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 3896 | 6818.0 | — | Sale at price 1.75 per share. | FINLEY JOHN DAVID | Chief Executive Officer | — | 2026-02-12 00:00:00 | D |
| 1 | 1989 | 3481.0 | — | Sale at price 1.75 per share. | JONES MITCHELL LAWRENCE | Officer | — | 2026-02-12 00:00:00 | D |
| 2 | 13333 | nan | — | — | FINLEY JOHN DAVID | Chief Executive Officer | — | 2026-02-11 00:00:00 | D |
| 3 | 8000 | nan | — | — | JONES MITCHELL LAWRENCE | Officer | — | 2026-02-11 00:00:00 | D |
| 4 | 5000 | 8356.0 | — | Purchase at price 1.67 per share. | WILLIAMS DONALD ALLEN | Director | — | 2026-01-16 00:00:00 | D |
| 5 | 5000 | 9400.0 | — | Purchase at price 1.88 per share. | WILLIAMS DONALD ALLEN | Director | — | 2026-01-09 00:00:00 | D |
| 6 | 388 | nan | — | — | WILLIAMS DONALD ALLEN | Director | — | 2024-11-21 00:00:00 | D |
| 7 | 388 | nan | — | — | WEI BINXIAN | Director | — | 2024-11-21 00:00:00 | D |
| 8 | 340 | nan | — | — | WILLIAMS DONALD ALLEN | Director | — | 2024-06-11 00:00:00 | D |
| 9 | 465 | nan | — | — | WEI BINXIAN | Director | — | 2024-06-11 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -14.42M | -12.06M | -12.72M | -14.16M |
| TotalUnusualItems | 0.00 | -225.00K | -1.52M | -10.05M |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -225.00K | -1.52M | -10.05M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -14.44M | -12.30M | -14.26M | -26.62M |
| ReconciledDepreciation | 3.00K | 4.00K | 3.00K | 2.00K |
| EBITDA | -14.42M | -12.28M | -14.24M | -24.22M |
| EBIT | -14.43M | -12.29M | -14.25M | -24.22M |
| NetInterestIncome | -12.00K | -15.00K | -13.00K | -3.08M |
| InterestExpense | 12.00K | 15.00K | 13.00K | 2.40M |
| NormalizedIncome | -14.44M | -12.07M | -12.74M | -16.56M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -14.44M | -12.30M | -14.26M | -26.62M |
| TotalExpenses | 14.86M | 13.10M | 15.31M | 11.74M |
| TotalOperatingIncomeAsReported | -14.86M | -13.07M | -15.72M | -41.85M |
| DilutedAverageShares | 1.42M | 456.01K | 58.69K | 12.46K |
| BasicAverageShares | 1.42M | 456.01K | 58.69K | 12.41K |
| DilutedEPS | -10.19 | -27.01 | -247.95 | -2.55K |
| BasicEPS | -10.19 | -27.01 | -247.95 | -2.14K |
| DilutedNIAvailtoComStockholders | -14.44M | -12.32M | -14.55M | -31.73M |
| AverageDilutionEarnings | 0.00 | -5.12M | ||
| NetIncomeCommonStockholders | -14.44M | -12.32M | -14.55M | -26.62M |
| OtherunderPreferredStockDividend | 0.00 | 16.00K | 288.00K | 0.00 |
| NetIncome | -14.44M | -12.30M | -14.26M | -26.62M |
| NetIncomeIncludingNoncontrollingInterests | -14.44M | -12.30M | -14.26M | -26.62M |
| NetIncomeContinuousOperations | -14.44M | -12.30M | -14.26M | -26.62M |
| PretaxIncome | -14.44M | -12.30M | -14.26M | -26.62M |
| OtherIncomeExpense | 433.00K | 560.00K | 1.06M | -11.79M |
| OtherNonOperatingIncomeExpenses | 433.00K | 785.00K | 2.58M | -1.74M |
| SpecialIncomeCharges | 0.00 | -225.00K | -410.00K | -29.84M |
| OtherSpecialCharges | 29.84M | |||
| RestructuringAndMergernAcquisition | 0.00 | 225.00K | 410.00K | 0.00 |
| GainOnSaleOfSecurity | -1.11M | 19.79M | ||
| NetNonOperatingInterestIncomeExpense | -12.00K | -15.00K | -13.00K | -3.08M |
| TotalOtherFinanceCost | 686.00K | |||
| InterestExpenseNonOperating | 12.00K | 15.00K | 13.00K | 2.40M |
| OperatingIncome | -14.86M | -12.85M | -15.31M | -11.74M |
| OperatingExpense | 14.86M | 13.10M | 15.31M | 11.74M |
| ResearchAndDevelopment | 9.06M | 6.89M | 6.55M | 2.43M |
| SellingGeneralAndAdministration | 5.80M | 6.20M | 8.76M | 9.31M |
| GeneralAndAdministrativeExpense | 5.80M | 6.20M | 8.76M | 9.31M |
| OtherGandA | 5.80M | 6.20M | 8.76M | 9.31M |
| TotalRevenue | 0.00 | 250.00K | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 250.00K | 0.00 | 0.00 |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|
| PreferredSharesNumber | 200.00K | 200.00K | 200.00K | |
| OrdinarySharesNumber | 2.97M | 818.06K | 396.29K | 218.99K |
| ShareIssued | 2.97M | 818.06K | 396.29K | 218.99K |
| TotalDebt | 169.00K | 369.00K | 404.00K | 199.00K |
| TangibleBookValue | 7.49M | 11.31M | 12.48M | 7.36M |
| InvestedCapital | 7.57M | 11.47M | 12.56M | 7.45M |
| WorkingCapital | 7.26M | 10.74M | 11.72M | 9.01M |
| NetTangibleAssets | 7.49M | 11.31M | 12.48M | 7.37M |
| CapitalLeaseObligations | 90.00K | 211.00K | 316.00K | 112.00K |
| CommonStockEquity | 7.49M | 11.31M | 12.48M | 7.36M |
| PreferredStockEquity | 2.00K | 2.00K | 2.00K | 2.00K |
| TotalCapitalization | 7.49M | 11.31M | 12.48M | 7.37M |
| TotalEquityGrossMinorityInterest | 7.49M | 11.31M | 12.48M | 7.37M |
| StockholdersEquity | 7.49M | 11.31M | 12.48M | 7.37M |
| RetainedEarnings | -135.94M | -121.51M | -109.19M | -94.64M |
| AdditionalPaidInCapital | 143.41M | 132.81M | 121.64M | 102.00M |
| CapitalStock | 29.00K | 8.00K | 32.00K | 5.00K |
| CommonStock | 27.00K | 6.00K | 30.00K | 3.00K |
| PreferredStock | 2.00K | 2.00K | 2.00K | 2.00K |
| TotalLiabilitiesNetMinorityInterest | 3.39M | 2.74M | 3.28M | 5.15M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 152.00K | 153.00K | 272.00K | 2.65M |
| OtherNonCurrentLiabilities | 150.00K | 61.00K | 61.00K | 2.65M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| DerivativeProductLiabilities | 2.00K | 2.00K | 61.00K | 2.65M |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 90.00K | 211.00K | 0.00 |
| LongTermCapitalLeaseObligation | 0.00 | 90.00K | 211.00K | 0.00 |
| CurrentLiabilities | 3.24M | 2.59M | 3.01M | 2.50M |
| CurrentDebtAndCapitalLeaseObligation | 169.00K | 279.00K | 193.00K | 199.00K |
| CurrentCapitalLeaseObligation | 90.00K | 121.00K | 105.00K | 112.00K |
| CurrentDebt | 79.00K | 158.00K | 88.00K | 87.00K |
| OtherCurrentBorrowings | 79.00K | 158.00K | 88.00K | 87.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 722.00K | 909.00K | 666.00K | 511.00K |
| PayablesAndAccruedExpenses | 2.35M | 1.40M | 2.15M | 1.79M |
| CurrentAccruedExpenses | 1.13M | 554.00K | 325.00K | 268.00K |
| Payables | 1.21M | 844.00K | 1.83M | 1.52M |
| AccountsPayable | 1.21M | 844.00K | 1.83M | 1.52M |
| TotalAssets | 10.88M | 14.05M | 15.76M | 12.51M |
| TotalNonCurrentAssets | 386.00K | 724.00K | 1.03M | 1.01M |
| OtherNonCurrentAssets | 26.00K | 38.00K | 38.00K | 26.00K |
| NonCurrentPrepaidAssets | 273.00K | 478.00K | 682.00K | 868.00K |
| NonCurrentDeferredAssets | 0.00 | |||
| NetPPE | 87.00K | 208.00K | 310.00K | 112.00K |
| GrossPPE | 87.00K | 208.00K | 310.00K | 112.00K |
| OtherProperties | 3.00K | 10.00K | 10.00K | 3.00K |
| MachineryFurnitureEquipment | 3.00K | |||
| BuildingsAndImprovements | 84.00K | 198.00K | 300.00K | 109.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 10.49M | 13.33M | 14.73M | 11.51M |
| CurrentDeferredAssets | 75.00K | 112.00K | 114.00K | 0.00 |
| PrepaidAssets | 574.00K | 636.00K | 798.00K | 861.00K |
| Receivables | 24.00K | 148.00K | 1.44M | 150.00K |
| OtherReceivables | 24.00K | 148.00K | 1.44M | 150.00K |
| AccountsReceivable | 0.00 | |||
| CashCashEquivalentsAndShortTermInvestments | 9.82M | 12.43M | 12.38M | 10.49M |
| CashAndCashEquivalents | 9.82M | 12.43M | 12.38M | 10.49M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -12.19M | -11.14M | -13.37M | -14.77M |
| RepaymentOfDebt | -426.00K | -391.00K | -790.00K | -1.43M |
| IssuanceOfDebt | 0.00 | 1.25M | ||
| IssuanceOfCapitalStock | 8.44M | 9.42M | 14.40M | 25.11M |
| CapitalExpenditure | -4.00K | -10.00K | ||
| InterestPaidSupplementalData | 14.00K | 14.00K | 12.00K | 64.00K |
| EndCashPosition | 9.85M | 12.46M | 12.41M | 10.52M |
| BeginningCashPosition | 12.46M | 12.41M | 10.52M | 739.00K |
| ChangesInCash | -2.61M | 49.00K | 1.89M | 9.78M |
| FinancingCashFlow | 9.58M | 11.19M | 15.26M | 24.61M |
| CashFlowFromContinuingFinancingActivities | 9.58M | 11.19M | 15.26M | 24.61M |
| NetOtherFinancingCharges | -944.00K | -617.00K | -627.00K | -218.00K |
| ProceedsFromStockOptionExercised | 2.52M | 2.77M | 2.27M | -99.00K |
| NetPreferredStockIssuance | 0.00 | 19.90M | ||
| PreferredStockIssuance | 0.00 | 19.90M | ||
| NetCommonStockIssuance | 8.44M | 9.42M | 14.40M | 5.21M |
| CommonStockIssuance | 8.44M | 9.42M | 14.40M | 5.21M |
| NetIssuancePaymentsOfDebt | -426.00K | -391.00K | -790.00K | -183.00K |
| NetShortTermDebtIssuance | -426.00K | -391.00K | -790.00K | |
| ShortTermDebtPayments | -426.00K | -391.00K | -790.00K | |
| NetLongTermDebtIssuance | -790.00K | -183.00K | ||
| LongTermDebtPayments | -790.00K | -1.43M | ||
| LongTermDebtIssuance | 0.00 | 1.25M | ||
| InvestingCashFlow | 0.00 | -4.00K | -10.00K | -54.00K |
| CashFlowFromContinuingInvestingActivities | 0.00 | -4.00K | -10.00K | -54.00K |
| NetBusinessPurchaseAndSale | 0.00 | -54.00K | ||
| SaleOfBusiness | 0.00 | 3.28M | ||
| PurchaseOfBusiness | 0.00 | -3.33M | ||
| NetPPEPurchaseAndSale | 0.00 | -4.00K | -10.00K | 0.00 |
| PurchaseOfPPE | 0.00 | -4.00K | -10.00K | 0.00 |
| OperatingCashFlow | -12.19M | -11.13M | -13.36M | -14.77M |
| CashFlowFromContinuingOperatingActivities | -12.19M | -11.13M | -13.36M | -14.77M |
| ChangeInWorkingCapital | 1.39M | 400.00K | 1.25M | -4.76M |
| ChangeInOtherWorkingCapital | 292.00K | -25.00K | -1.12M | |
| ChangeInOtherCurrentLiabilities | -121.00K | -105.00K | -151.00K | -168.00K |
| ChangeInPayablesAndAccruedExpense | 762.00K | -200.00K | 399.00K | -2.40M |
| ChangeInAccruedExpense | -56.00K | 292.00K | ||
| ChangeInPayable | 818.00K | -492.00K | ||
| ChangeInAccountPayable | 818.00K | -492.00K | ||
| ChangeInPrepaidAssets | 750.00K | 705.00K | 1.03M | -1.16M |
| ChangeInReceivables | 0.00 | 84.00K | ||
| OtherNonCashItems | 249.00K | -6.00K | -69.00K | 34.77M |
| StockBasedCompensation | 652.00K | 624.00K | 1.03M | 1.89M |
| DepreciationAmortizationDepletion | 3.00K | 4.00K | 3.00K | 2.00K |
| DepreciationAndAmortization | 3.00K | 4.00K | 3.00K | 2.00K |
| Depreciation | 3.00K | 4.00K | 3.00K | |
| OperatingGainsLosses | -50.00K | 145.00K | -1.32M | -20.07M |
| GainLossOnInvestmentSecurities | -54.00K | 145.00K | -1.32M | -19.79M |
| GainLossOnSaleOfPPE | 4.00K | 0.00 | ||
| NetIncomeFromContinuingOperations | -14.44M | -12.30M | -14.26M | -26.62M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PALI
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|